Cubist Systematic Strategies’s Viridian Therapeutics VRDN Stock Holding History

Cubist Systematic Strategies’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50,898	Closed	-$1.16M	–	3615
2024 Q3	$1.16M	Buy	+50,898	New	+$832K	0.01%	1738
2024 Q2	–	Sell	-69,430	Closed	-$1.22M	–	4095
2024 Q1	$1.22M	Buy	+69,430	New	+$1.35M	0.01%	2012
2020 Q1	–	Sell	-67	Closed	–	–	2483
2019 Q4	$0	Hold	67	–	–	﹤0.01%	2562
2019 Q3	$1K	Sell	67 -66	-50%	-$1.46K	﹤0.01%	2179
2019 Q2	$4K	Hold	133	–	–	﹤0.01%	2418
2019 Q1	$6K	Sell	133 -34	-20%	-$1.54K	﹤0.01%	2202
2018 Q4	$8K	Sell	167 -38	-19%	-$2.2K	﹤0.01%	1990
2018 Q3	$17K	Buy	+205	New	+$19.3K	﹤0.01%	1798

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Cubist Systematic Strategies's VRDN Position: Q4 2024 in Review

Cubist Systematic Strategies sold out of Viridian Therapeutics (VRDN) in Q4 2024, closing a stake of 50,898 shares — an estimated $1.16M sold.

Cubist Systematic Strategies first reported a position in VRDN in Q3 2018 and held it in 8 quarters. The position peaked at $1.22M in Q1 2024. 178 funds tracked by Wall St. Rank hold VRDN as of Q4 2024.

Cubist Systematic Strategies reported no remaining Viridian Therapeutics position as of Q4 2024 after selling out during the quarter.
Cubist Systematic Strategies sold 50,898 Viridian Therapeutics shares in Q4 2024, an estimated $1.16M.
Cubist Systematic Strategies first reported a position in Viridian Therapeutics in Q3 2018 and held it in 8 quarters.
Cubist Systematic Strategies's Viridian Therapeutics position peaked at $1.22M in Q1 2024.
178 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2024.

Based on Cubist Systematic Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.